Antiviral activity of bNAbs on cell to cell transmission of two T/F HIV-1 strains
| bNAbs | IC50 | |
| WITO | SUMA | |
| NIH45-46 | 3.1 | 13.9a |
| 3BNC60 | 3.4 | 3.3 |
| VRC01 | 14.3a | X |
| 8ANC195 | X | 3.7a |
| 10-1074 | 1.8 | 1.9 |
| PG16 | 0.05 | 0.3 |
| 10E8 | 9.4a | >15 |
| 3BC176 | X | X |
| bNAbs | IC50 | |
| WITO | SUMA | |
| NIH45-46 | 3.1 | 13.9a |
| 3BNC60 | 3.4 | 3.3 |
| VRC01 | 14.3a | X |
| 8ANC195 | X | 3.7a |
| 10-1074 | 1.8 | 1.9 |
| PG16 | 0.05 | 0.3 |
| 10E8 | 9.4a | >15 |
| 3BC176 | X | X |
Primary HIV-1 CD4+ T cells were infected with two T/F HIV-1 strains (WITO or SUMA). Infected cells were preincubated for 1 h with different doses of bNAbs before co-culture with autologous target cells stained with FarRed dye. After 48 h, the fraction of productively infected (Gag+) target cells was measured by flow cytometry. The median inhibitory concentrations (IC50) were calculated with cells from three to four independent donors. Bold indicates IC50 < 0.5 µg/ml; italics indicate IC50 = 0.5–2 µg/ml; single underline indicates IC50 = 2–10 µg/ml; bold and underline indicate IC50 = 10–15 µg/ml. X, no neutralization (<25% inhibition at 15 µg/ml).
Partial neutralization (<90% inhibition at 15 µg/ml).